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Abstract
Dendritic cells (DCs) and natural killer (NK) cells are both part of the innate immune 
system, also playing crucial functions in the regulation of adaptive immune responses. In 
recent years, numerous works have demonstrated that DCs and NK cells mutually influ-
ence each other with major consequences in the type and effectiveness of elicited immune 
responses. Among other effects, DC-NK crosstalk can result in NK cell activation and DC 
maturation or deletion, depending on its activation status. In this chapter and after a brief 
overview of DCs and NK immunobiology, we focus on the process of DC-NK crosstalk, 
highlighting the relevance of rationally exploring this interplay in the development of 
more effective cancer immunotherapies.
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1. Introduction
Dendritic cells (DCs) are a heterogeneous population of innate immune cells with unique 
capacity to process and present antigens to naïve T cells. They are, therefore, responsible for 
the orchestration of the adaptive immune responses, promoting either immunity or tolerance 
to self-antigens [1]. Given these unique characteristics, DCs have for long been used in clinical 
approaches, particularly to boost antitumor immune response during cancer treatment [2]. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The results gathered from more than 20 years of experimentation and almost 350 clinical tri-
als demonstrated that DC-based antitumor immunotherapy is safe and with relevant clinical 
outcomes [3].
One of the key observations from these experiments is that the success of DC-based vaccines 
relies not only on the capacity of these cells to polarize and activate T lymphocytes but also on 
their ability to bidirectionally interact with natural killer (NK) cells. In fact, it is known that an 
optimal antitumor immune response depends on a complex interplay between CD8+ T cells, 
CD4+ T cells and NK cells [4]. NK cells are large granular innate immune cells with cytotoxic 
functions. They are crucial for the initial defense against viral infections, destroying infected 
cells and also for the elimination of tumor cells or foreign and endogenous cells under stress 
[5]. The complex cell-to-cell crosstalk between DCs and NK cells has major consequences on 
the modulation of immune responses. Therefore, it is expected that the rational design of new 
DC-based immunotherapies encompasses this required interplay with NK cells in order to 
synergistically evoke a superior clinical outcome [6].
In this chapter, we focus on several key aspects: the DC and NK immunobiology, the mecha-
nisms and consequences of DC-NK bidirectional crosstalk, and the potential and relevance of 
DC-NK crosstalk in cancer immunotherapy.
2. Dendritic cells
2.1. Dendritic cells at a glance
DCs were first described by Paul Langerhans in 1868, being erroneously characterized as 
part of peripheral nervous system. It took almost 100 years to reveal the real functions of 
these cells. In 1973 and subsequent years, Ralph Steinman and Zanvil Cohn demonstrated by 
a series of elegant experiments that DCs are crucial regulators of both innate and acquired 
arms of the immune system [7, 8]. These cells have the unparalleled ability to polarize naïve 
T lymphocytes into their different effector or regulatory subsets and are potent enhancers of 
NK cell cytotoxicity [9, 10] as well as fundamental accessory cells in the production of primary 
antibody responses [11]. They also take part in the preservation of tolerance to antigens, with 
thymus DCs helping in the shaping of the T cell repertoire through the deletion of autoreac-
tive lymphocytes [12, 13].
Classically, DCs are found in an immature state at locations of possible antigen entry such 
as the skin and mucosal surfaces (e.g., genitourinary, gastrointestinal, and respiratory sys-
tems), as well as in the connective tissue of all solid organs and even in fat tissue, retina, and 
brain [8, 14–18]. Upon encountering a potential threat, DCs capture and process it, displaying 
the resultant antigens on major histocompatibility complex (MHC)-I or MHC-II molecules. 
During this process, DCs engage a program, termed maturation, characterized by several 
morphological, phenotypical and functional changes that strongly increase their immuno-
genic profile. Then, mature DCs enter draining lymphatic vessels and migrate to lymph nodes 
where they present processed antigens to naïve T lymphocytes, generating a specific immune 
response [19].
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2.2. Dendritic cell subsets and characteristics
DCs are composed of a very heterogeneous family of innate immune cells with characteristics 
frequently overlapping between subpopulations, making hard to define an unambiguous 
classification. Hence, in 2014, a novel classification system was created, first centered on DC 
ontogeny and then on their location, function, and phenotype [20].
Concerning ontogeny, all DC subpopulations are derived from a common hematopoietic 
CD34+ stem cell precursor that originates multiple intermediate precursors, which differ-
entiate into several DC subsets in a process that is highly dependent on hematopoietic 
cytokines and growth factors [8, 14, 21]. There are three major subpopulations of DCs: 
plasmacytoid DCs (pDCs) characterized by the expression of CD123, CD303, CD304, 
FCER1, ILT3, and ILT7; classical DCs 1 (cDC1) that express CD141, CLEC9A, XCR1, and 
CADM1; and classical DCs 2 expressing CD1c, CD11c, CD11b, CD2, FCER1, SIRPA, ILT1, 
and CLEC4A [2, 22, 23].
cDCs1 are 10 times less frequent than cDCs2 and can be found in the blood, lymph nodes, 
tonsil, spleen, bone marrow, and in non-lymphoid tissues such as skin, lung, intestine, and 
liver. Functionally, they are characterized by a high capacity to cross-present antigens via 
MHC class I to CD8+T cells, promoting their activation to cytotoxic T lymphocytes (CTLs) [24]. 
Although they secrete low amounts of IL-12 when compared to cDCs2 [25, 26], they are highly 
effective in promoting Th1 cell polarization and NK cell activation. This is in part due to the 
expression of the chemokine receptor XCR1, which enables cDCs1 to closely interact with 
XCL-producing cells such as activated T lymphocytes and NK cells [25–28]. cDCs1 are par-
ticularly equipped for the recognition of viral and intracellular antigens: they express TLR3, 
TLR9, and TLR10, also being major producers of type III interferons IFN λ 1–3 [29].
Regarding myeloid cDCs2, they are the major DC population being found in blood, spleen, 
skin, lung, and intestine. They express a large panel of pattern recognition receptors (PRRs) 
namely TLRs 2, 4, 5, 6, and 8, NOD-like receptors (NOD2, NLRP1, NLRP3, and NAIP), and 
lectin receptors such as DEC205, CLEC4A, CLEC6A, CLEC7A, CLEC10A, CLEC12A, and also 
the asialoglycoprotein receptor. Once activated, cDCs2 produce high amounts of IL-12 and 
also secrete IL-1, IL-6, IL-8, IL-10, IL-23, and tumor necrosis factor-alpha (TNF-α) [25, 30]. 
The different blood and tissue resident cDCs2 orchestrate a wide range of immune responses 
against viral, bacterial, fungal, and helminthic infections as a consequence of their capacity 
to polarize naïve T cells toward Th1, Th2, Th17, Th22, and CTL effector populations [30–32].
pDCs present a further limited distribution, being mainly found in blood and T cell areas 
of lymphoid organs. This DC subset is specifically tailored to sense and respond to viral 
infections [2, 8, 14, 33]. Indeed, pDCs highly express TLR7 and TLR9, the sensors for single-
stranded RNA and double-stranded DNA, respectively [34], and upon activation, they pro-
duce high quantities of type I and III interferons, TNF-α, IL-6, and granzyme B [35]. Due to 
their intrinsic capacity to cross-present antigens to CD8+ T cells, they also play a relevant role 
in antitumor immunity [36].
Finally, Langerhans cells, the main DCs found in the skin epidermis, are CD45+, MHC-II+, 
positive for Langerin, and have a low expression of CD11c and a high expression of CD1a. 
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They are exclusively derived from embryonic precursors and are able to self-renew locally 
[37]. At a functional level, Langerhans cells can induce immunogenic or tolerogenic responses 
upon specific maturation stimuli and cellular microenvironment and are particularly effective 
in antigen cross-presentation [38].
The phenotypical and functional characterization of human DC subsets is an exciting area 
that remains in continuous evolution. It is conceivable that this increased knowledge in 
DC immunobiology will empower their use in the design of more rational and effective 
immunotherapies.
3. NK cells
3.1. NK cell immunobiology
NK cells represent 5–15% of the circulating lymphocytes and play a pivotal role in host defense 
against pathogens and cancer [5]. Although recognized for their spontaneous killing ability of 
virus-infected or transformed cells without prior immunization, these cells also play an impor-
tant role in the modulation of immune responses through the secretion of multiple cytokines 
and chemokines [39]. Additionally, a growing body of evidence suggests that NK cells can 
mediate antigen-specific immunological memory, associated with adaptive immunity [40].
NK cell activity is tightly regulated by a complex array of germline-encoded activating and 
inhibitory receptors randomly generated during NK cell differentiation and maturation 
[41]. The integration of the signals transmitted by these receptors forms the basis of NK cell 
reactivity to their targets and determines the magnitude of NK cell–mediated cytotoxicity 
and cytokine production. The inhibitory receptors such as killer immunoglobulin-like recep-
tors (KIRs) and the lectin-like CD94/NKG2A heterodimer recognize self-molecules of the 
major histocompatibility complex (MHC) class I expressed in almost all healthy cell types 
and protect themselves from NK cell-mediated killing [42]. Paradoxically, the engagement of 
MHC class I molecules maintains NK cells in a state of responsiveness to subsequent activa-
tion, a property referred to as NK cell licensing [43]. During the course of tumorigenesis or 
viral infection, cells often decrease or even lose the expression of MHC class I molecules and 
upregulate the expression of a wide spectrum of stress-induced surface ligands that are rec-
ognized by activating receptors in NK cells, including the natural cytotoxic receptors (NCRs: 
NKp46, NKp30, and NKp44), the C-type lectin receptors (CD94/NKG2C, NKG2D, NKG2E/H, 
and NKG2F), DNAM-1, and killer immunoglobulin-like receptors with a short cytoplasmic 
tail (KIRs, KIR-2DS, and KIR-3DS) [41, 44]. When multiple of these activating receptors are 
simultaneously engaged and reach a threshold that surpass the inhibitory signals, NK cells 
are shifted to an activated phenotype, exerting their cytolytic activity against target cells [41, 
45]. Several cytokines have been described to activate and promote NK cells antitumor activ-
ity. The common gamma chain (γc) family of cytokines, like IL-2, IL-12, IL-15, IL-18 and IL-21, 
are the most well-recognized ILs to boost NK cell antitumor activities and have been used to 
improve the proliferation, differentiation and effector function of NK cells [46].
Regarding their cytolytic activity, the perforin/granzyme pathway is the main mechanism 
used by NK cells to kill target cells. Upon activation, NK cells polarize the lytic granules to 
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the immunological synapse formed with the target cell and release the membrane disrupting 
perforin that forms transient pores on the target cell membrane, allowing the entrance of 
granzymes, a family of serine proteases, that trigger an apoptotic-like cell death [47]. The 
death receptor pathways involving FasL and TRAIL are also employed by NK cells on target 
cell-induced apoptosis through a perforin-independent mechanism. Death receptor members 
of the TNF-α family such as FAS and the death receptor 5 (DR5) are usually upregulated in 
tumor cells and transduce apoptotic signals upon binding to their cognate ligands FasL and 
TRAIL on NK cells, resulting in a classical caspase-dependent apoptosis [48]. NK cells are also 
mediators of the antibody-dependent cellular cytotoxicity (ADCC), another type of granule-
mediated cell death that occurs when the Fc receptor expressed by NK cells (FcγRIII or CD16) 
binds to the Fc portion of IgG1 antibodies-coated target cells [49]. This interaction results in a 
strong activation signal that overcomes the inhibitory signals, leading to a downstream cas-
cade of activation events with the release of cytolytic granules and inflammatory mediators.
In addition to the direct cytotoxic mechanisms, NK cells also act as immunomodulatory cells 
engaged in reciprocal interactions with DCs, macrophages, and T cells through the release 
of various cytokines, chemokines and growth factors, which might augment or dampen 
immune responses [50].
4. DC-NK cell interplay
Currently, it is clear that DCs and NK cells have a crucial role in modulating innate and 
adaptive immune responses through a complex cell-to-cell crosstalk (Figure 1). Indeed, 
DC-mediated activation of NK cells contributes to the development of potent innate immu-
nity, whereas, in turn, activated NK cells provide signals for DC activation, maturation, and 
cytokine production, promoting adaptive immunity [6]. This DC-NK crosstalk occurs, in vivo, 
in the lymph nodes [51, 52], at the sites of inflammation, in peripheral tissues such as the skin 
and mucosa [53] and in solid tumor microenvironments [54].
4.1. Activation of NK cells by DCs
Several studies have demonstrated the potential of DCs to influence the function of NK cells. 
Seminal works revealed a reduction of NK cell-dependent antitumor effects in mice depleted 
from CD8α DCs, suggesting a direct role of DCs in NK cells activation [55]. The triggering of NK 
cells by DCs seems to be dependent on both cell-to-cell contact and soluble factors. Accordingly, 
in human and animal studies, NK cells activation by DCs was significantly disrupted by tran-
swell separation, reinforcing a major contribution of cell-to-cell contact to this close commu-
nication [55, 56]. Further studies have demonstrated that DC-produced IL-12 is also crucial 
for NK cells activation, namely for their production of IFN-γ [57]. This process comprises the 
formation of stimulatory synapses between DCs and NK cells, which promote the polarized 
secretion of pre-assembled stores of IL-12 by DCs toward NK cells [58]. Furthermore, Poly(I:C)-
treated DCs and IFN-α-treated DCs also induce NK cells to secrete IFN-γ by the binding of 
activating NK cell receptor NKG2D to its specific ligands, such as MHC class I-related chains 
A and B (MICA/B) [59, 60]. Another relevant interaction that results in NK cell cytotoxicity and 
IFN-γ release occurs between CXC3CL1 expressed on DCs and CXC3CR1 on NK cells [61].
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IL-15 can be considered as an additional and important cytokine involved in the process of 
DC-mediated activation of NK cells. This cytokine can be found bounded to DCs membrane 
and is able to induce NK cell proliferation, survival, and to enhance their cytotoxic functions 
[57, 62]. Additionally, in DCs, transmembrane TNF, as well as membrane-bound IL-15, can 
enhance NK cells proliferation, CD69 expression, and IFN-γ secretion [63]. Both signaling 
mechanisms are mediated by cell-to-cell contact via simultaneous engagement of DCs trans-
membrane TNF and membrane-bound IL-15, with their respective NK cell receptors, lead-
ing to its activation. Furthermore, NK cells proliferation is also dependent on the interaction 
between CD40 and B7 molecules on DCs with CD40L and CD28 on NK cells, respectively [64].
IL-18 expressed by immature and mature DCs has also been implicated in NK cells activation. 
DC-derived IL-18, as well as IL-12, is involved in the upregulation of NK cell cytotoxicity [56]. 
Figure 1. Dendritic cell-natural killer cell interplay. iDCs can undergo maturation by exposure to several stimuli, 
pathogen-associated molecular patterns (PAMPs), and IFN. The resulting mDCs secrete IL-12, IL-18, IL-15 and type 
I IFN, which in turn induce the proliferation and activation of NK cells, leading to further secretion of IFN-γ. NK-DC 
interaction by NKG2D with MICA/B and CXC3CR1 with CXC3CL1 can also lead to NK cell activation. Thus, activated 
NK cells are able to increase DC maturation, dependent on cytokines like IFN-γ and TNF-α, as well as the interaction 
of NKp30 receptor on NK cells with its ligand on DCs. On the other hand, activated NK cells can also eliminate MHC-I 
low-expressing iDCs by cell contact-dependent interactions of NKp30 receptor with NKp30 ligand and DNAM-1 with 
Nectin-2 or PVR. iDCs, immature dendritic cells; IFN, interferon; mDCs, mature dendritic cells.
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Similar to IL-12, IL-18 seems to be delivered in secretory lysosomes at the NK/DC synaptic 
cleft, leading to NK cells activation [65]. In case of regulatory DCs, their insufficient produc-
tion of IL-18 is involved in the restrained IFN-γ secretion by NK cells, downregulating NK 
cells activation [66]. In addition, studies performed in mice revealed that both IL-18 and IL-12 
are also involved in the expansion of Ly49H+ NK cells promoted by CD8α+ DCs [67].
The role of type I IFN (IFN-α/β) on NK cell activation has also been assessed during NK-DCs 
crosstalk. Type I IFN, secreted by plasmacytoid DCs [68], is required for NK cell cytotoxicity 
in response to virus infection [69, 70]. In the context of TLR stimulation, NK cells priming is 
dependent on the recognition of type I IFN signals by DCs and on the subsequent production 
and trans-presentation of IL-15 by DCs to resting NK cells [71]. Finally, IL-2 produced by 
bacterially activated myeloid DCs has also been shown to be required, both in vitro and in 
vivo, for NK cells activation and IFN-γ-efficient production [72].
4.2. DC modulation by activated NK cells
Over the last two decades, multiple studies have reported that NK cells play a relevant role 
in the DCs maturation process, either by killing DCs that did not properly acquire a mature 
phenotype or through direct DCs stimulation [73]. The process of immature DC lysis is 
dependent on NK-activating receptors as well as on the amount of MHC class I molecules on 
DCs [74, 75]. In vitro assays have demonstrated that activated NK cells can recognize and kill 
DCs via NKp30 natural cytotoxicity receptor, suggesting the expression of a still unknown 
NKp30 ligand on DCs surface. Mature DCs are susceptible to NK cell killing when NK inhibi-
tory signal is blocked by MCH-I antibodies, confirming that mature DCs are naturally spared 
due to their high expression of MHC class I molecules [76]. In addition, DNAM-1-triggering 
receptor and its ligands, poliovirus receptor (PVR) and Nectin-2, have been demonstrated to 
be crucial in NK cell-mediated lysis of immature DCs. DNAM-1 receptor on NK cells cooper-
ates with NKp30 receptor in the NK-mediated elimination of DCs. The degree of contribu-
tion of DNAM-1 appeared to correlate with the surface amount of its specific ligands PVR 
and Nectin-2 on DCs [77]. Other in vivo studies have also shown that NK cells efficiently kill 
injected immature bone marrow-derived DCs, via a pathway dependent on the TNF-related 
apoptosis-inducing ligand (TRAIL) [78]. Similarly, another study confirmed that NK cells can 
kill incompletely matured DCs in the context of a viral infection via TRAIL—Death Receptor 
4 (DR4) pathway [79]. These findings led to the hypothesis that the killing of immature DCs 
by NK cells should promote the survival of the most immunogenic DCs, supporting and 
empowering efficient and protective immune responses. In fact, it has been demonstrated that 
the killing of immature DCs by autologous NK cells is particularly important for the expan-
sion of cancer-specific CTLs [80].
On the other hand, in chronic viral infections, IL-10 produced by NK cells induces contrasting 
phenotypic changes in DCs; specifically, immature DCs exhibit aberrant resistance to NK 
cell-mediated elimination, whereas mature DCs had an increased susceptibility to NKG2D-
dependent elimination. This process leads to the accumulation of poorly immunogenic DCs 
in lymph nodes, causing a progressive immune dysfunction [81]. Furthermore, DC lysis by 
NK cells can also negatively regulate the duration and effectiveness of virus-specific T cell 
responses in vivo by limiting the exposure of T cells to infected antigen-presenting cells, which 
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negatively impacts the quality of T cell responses and their ability to limit viral persistence 
[82]. Additionally, it has been shown that in solid organ transplantation, host NK cells kill 
allogeneic DCs via the perforin pathway. This will limit allogeneic antigen presentation to 
host lymphocytes, reducing T cell–mediated graft-versus-host disease [83].
Activated NK cells can also improve DCs maturation and activation, enhancing their ability to 
stimulate T cell responses. When NK cells are cultured with immature DCs in the presence of 
maturation stimuli, such as lipopolysaccharide (LPS), they strongly enhance DCs maturation, 
specifically by upregulating the DCs co-stimulatory molecule CD86 and IL-12 production. 
NK cells activated by IL-2 are also able to induce DCs maturation, improving their ability to 
stimulate allogeneic naïve CD4+ T cells. These effects of NK cells on DCs maturation are cell 
contact dependent, although the secretion of IFN-γ and TNF-α is also relevant [84, 85]. These 
findings show that both effects of NK cells on DCs (DC killing and stimulation) are dependent 
on NKp30-triggering receptor.
Further studies have shown that NK cell-activated DCs produce higher levels of IL12p70 
after subsequent CD40 ligands stimulation, leading to an increase in the induction of T cell 
responses [86, 87]. The effect of NK cells on DCs is also dependent on the type of NK cell 
activation; IL-2-primed “effector” NK cells can kill DCs, whereas IL-18-primed NK cells are 
just prone to enhance the ability of DCs to produce IL-12p70 dependent on CD40L stimula-
tion [88]. In fact, NK cells are able to trigger immature DCs to secrete IL-18 through a Ca2+-
dependent and tubulin-mediated recruitment of IL-18-containing secretory lysosomes toward 
the adhering NK cell. Then, IL18-activated NK cells secrete the pro-inflammatory “danger 
signal” high-mobility group B1 (HMGB1), which induces DC maturation and protects DCs 
from lysis, thus favoring the development of adaptive immune responses [65]. Furthermore, 
human NK cells, exposed to different cytokines, are able to promote distinct pathways of Th1 
priming. Specifically, IL-12- or IL-2-activated NK cells induce maturation of DCs capable of 
priming IFN-γ-producing Th1 cells, whereas IL-18-conditioned NK cells induce Th1 polariza-
tion only when co-cultured with both DCs and T cells, which release IL-12 and IL-2, respec-
tively, promoting IFN-γ production. Thus, the local prevalence of IL-12, IL-2, and IL-18 at the 
inflammatory sites may differentially modulate the NK cell interaction with DCs, leading to 
different outcomes in naïve T cell polarization [89].
Recently, IL-23 was uncovered as an enhancer of NK cell ability to stimulate DCs. IL-23 
induces NK cells activation and displays a synergistic effect with IL-18 for IFN-γ production 
by NK cells. This cytokine also potentiates the increase of CD86 expression and IL-12 secre-
tion by LPS-treated DCs upon IL-18-stimulated NK cells contact [90].
5. DCs and NK cells in cancer immunotherapy
The main purpose of cancer immunotherapy is to change the balance from tumor escape or 
equilibrium to cancer cells elimination. Latest developments have been focused at increasing 
the activation status of the innate and adaptive immune systems, comprising cytokine admin-
istration, Car T cells, DCs and NK-based vaccines, checkpoint inhibitors and monoclonal 
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antibodies engineered to target high-yield elements in oncogenic-signaling pathways [91]. A 
crucial point for the development of such approaches was the definition of the optimal char-
acteristics of an antitumor immune response. Specifically, it became evident that this response 
depends on a complex cells interplay involving DCs, CD8+ T cells, CD4+ T cells, and NK cells.
Given their positioning at the interface between innate and adaptive immunities and 
their unparalleled capacity to interact and modulate immune effector cells, DCs have 
been scrutinized and settled as highly desirable and full of translational and clinical 
potential. Since the 1990s, DCs have been used in more than 350 clinical trials as cellular 
antitumor vaccines [3]. Currently, there are three approaches exploring DCs in oncologic 
treatments: (1) non-targeted protein and nucleic acids-based vaccines captured by DCs in 
vivo; (2) direct targeting of antigens to DCs in vivo; and (3) vaccines composed of ex vivo-
generated DCs matured and loaded with tumor antigens [19]. Notwithstanding the good 
safety profile of antitumor DC-based vaccines, the rate of success in inducing clear thera-
peutic outcomes is inconsistent [3]. Objective tumor responses are usually above 15% [92], 
and promising vaccines in early-phase studies [93, 94] often fail to present clinical benefits 
in pivotal phase III trials [95]. Differentiation of DCs ex vivo from blood monocytes fol-
lowed by their injection back into the patient is by far the most common strategy [1, 8]. 
This approach suffers from some limitations: very few of the injected DCs migrate to the 
lymph nodes to present antigens to T cells, and it became evident that monocyte-derived 
DCs are functionally limited when compared to endogenous DCs subpopulations [96, 97]. 
In vivo targeting of antigens to specific DC subsets, tailoring of ex vivo differentiated DCs 
to particular phenotypes, and the combination of DCs-based vaccines with other antitumor 
therapies are critical steps for the effective success of new DCs immunotherapies [2–4, 92].
As referred in the earlier section, NK cells can directly eliminate tumor cells and indirectly 
enhance antitumor adaptive immunity by favoring DCs maturation and by killing immature 
DCs, thus enhancing immunogenic DC populations that will polarize antigen-specific CTLs 
[76, 98]. Importantly, the cell debris resultant from NK tumor cell destruction is also an impor-
tant source of multiple tumor antigens for DCs cross-presentation to CD8+ T cells [99]. Due to 
these characteristics, NK cells have been clinically explored in recent years in several immuno-
therapeutic strategies for cancer. There are mainly two therapeutic approaches based on NK 
cells: the use of NK cell stimulants/modulators to take advantage of endogenous responses 
and the adoptive cell transfers of fully differentiated and ex vivo-activated NK cells [100, 101]. 
The adoptive cell transfers of autologous NK cells have been tested and well tolerated in the 
treatment of several cancers, including glioma, lymphoma, and renal cell carcinoma, though 
clinical responses have not always been observed [102, 103].
6. Future perspectives
In parallel with the growing knowledge on immune cells and cancer biology, cell-based 
immunotherapies must be tailored to answer the new demands. Whereas initial research 
focused on generating mainly tumor CTLs responses, it becomes clear that the activation of 
multiple immune effector cells is the key to success for curative cancer vaccination.
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Apart from CTL induction, DC-NK cell crosstalk is of major importance in antitumor immune 
responses [4]. Efficient DC-vaccine-mediated antitumor immunity has been shown to be strongly 
dependent on NK cell activity [6]. This was highlighted by experiments where NK cell deple-
tion drastically impacted tumor elimination following DC vaccination [104, 105]. Moreover, 
data from several clinical trials on DC-based antitumor vaccines indicate that positive outcomes 
seem to correlate with high levels of activated NK cells in responder patients [106].
Taken together, these data underscore why future research efforts should also focus on optimiz-
ing the NK cell–interacting properties of DC vaccines, in addition to improving their T cell–stim-
ulatory capacity. The NK cell–activating character of DC vaccine preparations can be imprinted 
at multiple levels, such as by (1) tailoring the phenotype of ex vivo differentiated DCs, (2) using 
specific DCs subsets, and (3) targeting endogenous DCs populations that are intrinsically prone 
to interact with NK cells. The former approach includes the use of DCs expressing high levels of 
Figure 2. DC-NK cell crosstalk in cancer. NK cells can be activated by DCs, directly by cell contact and/or by DC-produced 
cytokines such as IL-12, IL-15 and IL18. Activated NK cells can then proliferate and secrete cytokines like IFN-γ, which 
will stimulate antitumor-acquired immune response. Specifically, IFN-γ induces CD8+ T cells to convert into antigen-
specific CTLs and supports the creation of immunological memory against the tumor antigens. Additionally, IFN-γ can 
also stimulate the polarization of CD4+ T cells into Th1 subset that in turn stimulates CTL differentiation. Furthermore, 
activated NK cells, additionally to induce DCs maturation, will destroy tumor cells, fueling DCs with tumor antigens 
that are then cross-presented to CD8+ T cells. The cDCs1 population (CD141+ XCRI+) is particularly effective in this 
interplay: The expression of XCR1 receptor by this DC subset and of its ligand XCL1 by T and NK cells during infectious 
and inflammatory responses potentiates the interaction between these cells. Additionally, CD141+ XCRI+ DCs present 
an exceptional antigen cross-presentation capacity and are producers of high amounts of IL-12 following activation. 
CD-40 L, CD-40 ligand; IFN-γ, interferon γ; IL, interleukin; TAA, tumor-associated antigens; TCR, T cell receptor; XCL1, 
chemokine (C motif) ligand; XCR1, chemokine receptor for XCL1.
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IL-12 and IL-15 [107] or manipulated to express the receptor XCR1. On the other hand, the other 
potential strategy is to target endogenous DCs subsets expressing XCR1. By using/targeting 
XCR1 expressing DCs, we potentiate their interaction with activated CD8+T cells and NK cell, 
given that these are the main producers of the XCR1 ligand XCL1 (Figure 2) [26, 27, 108].
In conclusion, the design of new DC-based vaccination strategies should encompass NK cell-
stimulating potency. Additionally, it would be of great value to systematically incorporate 
NK cells monitoring as an outcome in antitumor DC-based clinical trials.
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